There were an estimated 58,240 new cases and 13,040 deaths from kidney cancer in the United States in 2010. The increased treatment and cure of small, incidentally discovered renal tumors,…
The majority of kidney cancer tumors are small renal masses (SRMs). Partial nephrectomy is now established as the preferred treatment modality. In some patients the potential morbidity may outweigh the…
Imaging plays a central role in the detection, diagnosis, staging, and follow-up of renal cell carcinoma (RCC). Most renal masses are incidentally detected with modern, high-resolution imaging techniques and a…
Renal cell cancer (RCC) is increasingly diagnosed at an early stage in many countries, which likely contributes to the recent leveling of RCC mortality in the United States and many…
Toni K. Choueiri, MD, Guest Editor Since December 2005 and as of August 2011, the date of this issue, six “targeted” drugs have been approved in metastatic renal cell carcinoma…
The current treatment paradigm for metastatic renal cell carcinoma (RCC) includes agents that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. Because these agents…
The advent of targeted agents for the treatment of advanced renal cell carcinoma has led to dramatic improvements in therapy. However, the chronic use of these medications has also led…
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the…
Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion…
Although several cytokines have shown antitumor activity in renal cell carcinoma (RCC), the most consistent results have been reported with interleukin-2 (IL-2) and interferon (IFN). Recent insights into how the…
